Table 2.
Comparison of selected hemodynamic and quality of life results at baseline (day 0) in dogs treated with sildenafil or tadalafil.
| Treatment | |||||
|---|---|---|---|---|---|
| Variable | n | Sildenafil | n | Tadalafil | p-value |
| Peak TRFV (m/s) | 8 | 3.80 (0.69) | 9 | 4.05 (0.54) | 0.41a |
| Estimated sPAP (mmHg) | 8 | 66.90 (20.10) | 9 | 72.90 (20.00) | 0.55a |
| PRPV (m/s) | 4 | 2.97 (0.57) | 4 | 3.09 (0.33) | 0.74a |
| Type III profiles (yes/total) | 8 | 5/8 | 8 | 4/8 | 1.00b |
| AT:ET | 8 | 0.23 (0.19, 0.33) | 8 | 0.24 (0.19, 0.37) | 0.72c |
| RPAD (%) | 7 | 9.30 (6.50, 20.50) | 7 | 16.7 (14.70, 18.70) | 0.13c |
| FETCH-questionnaire score (0–85) | 10 | 17.60 (13.90) | 11 | 27.0 (21.00) | 0.25a |
| VAS-A (0–10mm) | 10 | 3.60 (1.10,6.60) | 11 | 1.40 (0.30,5.00) | 0.32c |
| VAS-B (0–10mm) | 10 | 3.80 (2.80) | 11 | 3.60 (2.70) | 0.85a |
AT:ET: acceleration time (AT) indexed to the ejection time (ET) of pulmonary artery flow; time PRPV: pulmonary regurgitation peak velocity; RPAD: right pulmonary artery dispensability index; FETCH: functional evaluation of cardiac health; m: meter; mmHg: millimeter of mercury; mm: millimeter; n: number; sPAP: systolic pulmonary arterial pressure; s: second; TRFV: tricuspid regurgitant flow velocity; VAS-A: visual analog score 24 hours before evaluation period; VAS-B: visual analog score 7 days before evaluation period.
Parametric continuous data presented as mean (SD) and compared with a two-tailed Student’s t-test,
categorical data presented as a proportion (yes/total) and compared with a Fischer Exact test,
non-parametric continuous data presented as median (Q1, Q3) and compared with a Mann-Whitney Rank Sum Test.